CA2335062A1 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions Download PDF

Info

Publication number
CA2335062A1
CA2335062A1 CA002335062A CA2335062A CA2335062A1 CA 2335062 A1 CA2335062 A1 CA 2335062A1 CA 002335062 A CA002335062 A CA 002335062A CA 2335062 A CA2335062 A CA 2335062A CA 2335062 A1 CA2335062 A1 CA 2335062A1
Authority
CA
Canada
Prior art keywords
acid
methyl
phenyl
biphenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002335062A
Other languages
English (en)
French (fr)
Inventor
Thomas Michael Andrew Bocan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2335062A1 publication Critical patent/CA2335062A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CA002335062A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions Abandoned CA2335062A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
US60/093,639 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
CA2335062A1 true CA2335062A1 (en) 2000-02-03

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002335062A Abandoned CA2335062A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (cs)
JP (1) JP2002521328A (cs)
KR (1) KR20010083134A (cs)
CN (1) CN1310629A (cs)
AP (1) AP2001002035A0 (cs)
AU (1) AU4701799A (cs)
BG (1) BG105162A (cs)
BR (1) BR9912296A (cs)
CA (1) CA2335062A1 (cs)
CZ (1) CZ2001126A3 (cs)
EA (1) EA200100153A1 (cs)
EE (1) EE200100046A (cs)
HR (1) HRP20010055A2 (cs)
HU (1) HUP0102880A3 (cs)
ID (1) ID30030A (cs)
IL (1) IL140982A0 (cs)
IS (1) IS5809A (cs)
NO (1) NO20010291L (cs)
OA (1) OA11584A (cs)
PL (1) PL346011A1 (cs)
SK (1) SK502001A3 (cs)
TR (1) TR200100205T2 (cs)
WO (1) WO2000004892A2 (cs)
YU (1) YU3501A (cs)
ZA (1) ZA200100294B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229907A1 (en) * 1999-11-05 2002-08-14 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
RU2246302C2 (ru) * 2000-09-01 2005-02-20 Санкио Компани, Лимитед Фармацевтическая композиция для профилактики и лечения нарушений липидного обмена
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DE60321775D1 (de) * 2002-04-03 2008-08-07 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
KR101011373B1 (ko) * 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 n-히드록시아미드 유도체
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
EP0841913B1 (en) * 1995-08-04 2003-02-05 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
ES2167733T3 (es) * 1996-05-17 2002-05-16 Warner Lambert Co Inhibidores de metaloproteinasa matricial de bifenilsulfonamida.
JP2000517341A (ja) * 1996-09-04 2000-12-26 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用

Also Published As

Publication number Publication date
ID30030A (id) 2001-11-01
AP2001002035A0 (en) 2001-03-31
JP2002521328A (ja) 2002-07-16
HUP0102880A2 (en) 2002-06-29
ZA200100294B (en) 2002-01-10
YU3501A (sh) 2005-06-10
OA11584A (en) 2004-07-20
AU4701799A (en) 2000-02-14
EP1098662A2 (en) 2001-05-16
WO2000004892A3 (en) 2000-05-18
NO20010291D0 (no) 2001-01-18
NO20010291L (no) 2001-01-18
IS5809A (is) 2001-01-12
CZ2001126A3 (cs) 2002-01-16
HRP20010055A2 (en) 2002-04-30
SK502001A3 (en) 2002-06-04
WO2000004892A2 (en) 2000-02-03
KR20010083134A (ko) 2001-08-31
EA200100153A1 (ru) 2001-08-27
EE200100046A (et) 2002-06-17
BR9912296A (pt) 2001-04-17
TR200100205T2 (tr) 2001-05-21
BG105162A (en) 2001-12-29
IL140982A0 (en) 2002-02-10
PL346011A1 (en) 2002-01-14
CN1310629A (zh) 2001-08-29
HUP0102880A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
US6133304A (en) ACE inhibitor-MMP inhibitor combinations
AU737117B2 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
CA2335062A1 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
US20020049237A1 (en) Statin-MMP inhibitor combinations
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
US20050020607A1 (en) Statin-MMP inhibitor combinations
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations
HK1038317A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued